Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

MedImmune initiates phase I study of MEDI-9197 for solid tumor cancers

Oct. 8, 2015

FDA places clinical hold on axalimogene filolisbac

Oct. 7, 2015

Biosimilar ONS-1045 meets primary and secondary endpoints in phase I trial

Oct. 7, 2015

Nivolumab shows enhanced overall survival in mRCC patients

Oct. 6, 2015

FDA approves Keytruda and companion diagnostic for PD-L1-expressing NSCLC tumors

Oct. 5, 2015

MedImmune and 3M Drug Delivery Systems collaborate to develop next-generation TLR agonists

Sep. 30, 2015

Advaxis initiates phase I study of ADXS-HER2 for HER2-expressing solid tumors

Sep. 30, 2015

CIRM grants USD 19.9 million to ImmunoCellular for the funding of ICT-107

Sep. 29, 2015

EMA CHMP grants accelerated assessment of Janssen's daratumumab for MM

Sep. 25, 2015

Genmab and Novartis granted priority review for ofatumumab sBLA

Sep. 21, 2015

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...